Moderna, Merck announce US FDA grants breakthrough therapy status to mRNA-4157/V940 in combo with Keytruda for adjuvant treatment of patients with high-risk melanoma following complete resection

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck, known as MSD outside of the United States and Canada, announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda, Merck